KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Pasithea Therapeutics Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.41−0.01 (-1.83%)
Close on Oct 19, 2026
- Market cap
- $13.23M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.3187 (−43.60%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $13.23M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.27
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$21.29M
- EPS, diluted
- -$1.48
- Book value per share
- $1.55
- Diluted shares
- 32M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$23.96M
Net income
-$21.29M
EPS, diluted
-$1.48
Free cash flow
–
Reported periodTrailing twelve months